{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:07:29Z","timestamp":1765807649823,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kyowa-Kirin"},{"DOI":"10.13039\/100012781","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli-Lilly"},{"DOI":"10.13039\/501100007033","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Medical Association","award":["CCT-B-2404"],"award-info":[{"award-number":["CCT-B-2404"]}]},{"name":"Clinical Trail Coordinating Center"},{"name":"Kitasato Academic Research Organization"},{"DOI":"10.13039\/501100007830","name":"Kitasato University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007830","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejca.2018.11.014","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T18:15:29Z","timestamp":1548785729000},"page":"84-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["A phase I\/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-7611","authenticated-orcid":false,"given":"Kan","family":"Yonemori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikiya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harukaze","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Michimae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamie","family":"Sukigara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.11.014_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-016-3106-7","article-title":"Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours","volume":"78","author":"Yonemori","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2018.11.014_bib2","doi-asserted-by":"crossref","first-page":"79175","DOI":"10.18632\/oncotarget.16577","article-title":"Phase I\/Ib study of olaparib and carboplatin in women with triple negative breast cancer","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2018.11.014_bib3","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib5","first-page":"113S","article-title":"Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer","volume":"18","author":"Robson","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib6","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/sj.onc.1209876","article-title":"Basal-like breast cancer and the BRCA1 phenotype","volume":"25","author":"Turner","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2018.11.014_bib7","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib8","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.onc.1210014","article-title":"BRCA1 dysfunction in sporadic basal-like breast cancer","volume":"26","author":"Turner","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2018.11.014_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2018.11.014_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10147-008-0831-x","article-title":"Basal-like subtype and BRCA1 dysfunction in breast cancers","volume":"13","author":"Miyoshi","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ijc.21004","article-title":"High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses","volume":"116","author":"Abd El-Rehim","year":"2005","journal-title":"Int J Canc"},{"year":"2015","series-title":"Phamacodynamic assay by ELISA for assessing PARP activity inhibition in a phase 1 study of eribulin plus olaparib","author":"Hashimto","key":"10.1016\/j.ejca.2018.11.014_bib12"},{"key":"10.1016\/j.ejca.2018.11.014_bib13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.11.014_bib15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","article-title":"Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy","volume":"27","author":"Pivot","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","article-title":"An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib","volume":"11","author":"Mateo","year":"2016","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib17","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","article-title":"A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors","volume":"18","author":"Rajan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2018.11.014_bib18","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","article-title":"A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer","volume":"49","author":"Liu","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.11.014_bib19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/bjc.2011.8","article-title":"A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours","volume":"104","author":"Khan","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.11.014_bib20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/bjc.2014.345","article-title":"Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours","volume":"111","author":"Del Conte","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.11.014_bib21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2011.555","article-title":"Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours","volume":"106","author":"Dean","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.11.014_bib22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","article-title":"Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors","volume":"25","author":"Balmana","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib23","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","article-title":"Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study","volume":"30","author":"Samol","year":"2012","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.ejca.2018.11.014_bib24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","article-title":"A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer","volume":"23","author":"Aogi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib26","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.11.014_bib27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"year":"2017","series-title":"AbstPD6-13Phase 1b\/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer","author":"Tolaney","key":"10.1016\/j.ejca.2018.11.014_bib28"},{"year":"2017","series-title":"Abst:PD6-11An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)","author":"Domchek","key":"10.1016\/j.ejca.2018.11.014_bib29"},{"year":"2017","series-title":"Abst:PD6-14Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer","author":"Yau","key":"10.1016\/j.ejca.2018.11.014_bib30"},{"key":"10.1016\/j.ejca.2018.11.014_bib31","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1111\/cas.13799","article-title":"Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy","volume":"109","author":"Prasanna","year":"2018","journal-title":"Cancer Sci"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:37Z","timestamp":1760732617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"alternative-id":["S0959804918315120"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I\/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}